Date: 2015-06-19
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO)
Company: RestorGenex (USA - IL)
Product: RES-529 (8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one)
Action
mechanism: kinase inhibitor. RES-529 is a first-in-class inhibitor of the PI3K/Akt/mTOR pathway. Signaling components of the PI3K pathway are central regulators of cell proliferation, growth, differentiation, survival and angiogenesis. It was developed from a non-steroidal, small molecule drug library through computational design, synthetic and medicinal chemistry. Through a series of in vitro and in vivo animal models, RES-529 has been shown to have activity in several cancer types due to its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway, specifically as a first-in-class allosteric, dissociative inhibitor of both TORC1 and TORC2.
Disease: prostate cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On June 19, 2015, RestorGenex, a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that in vitro and in vivo data will be presented on the use of RES-529 in a prostate cancer cell model. The data titled, \"RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model\" will be presented by Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Universita degli Studi dell\'Aquila, at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO), on June 22, 2015 in Rome, Italy.
\"Dr. Festuccia has studied TORC1 and TORC2 inhibition extensively in various cancer models. His work on RES-529 has provided RestorGenex with key compound information that has been integral to our research and development planning. The reported study investigated the role of TORC1 and TORC2 in proliferation and apoptosis induced by hormone manipulation in both androgen sensitive and castration resistant prostate cancer models. In addition, Professor Festuccia and his team evaluated the potential for combination treatment of RES-529 induced TORC1/TORC2 inhibition with hormonal therapy in both in vitro and in vivo models,\" stated Mark Weinberg, MD, MBA, senior vice president of clinical development for RestorGenex. \"We look forward to Professor Festuccia\'s presentation and conclusions at the close of the Congress.\"
